Clinical trials: Paramyxoviridae Infections
Mumps, Influenza
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students
This study is a randomized, controlled, open-label phase Ⅳ clinical trial of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
- Trial name
- NCT06208683
- Testing
- Mumps vaccine, Live (MV), Influenza Vaccine, inactivated, quadrivlent(QIV)
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Measles, Mumps
ProQuad® Intramuscular vs Subcutaneous
Primary objective: To demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in terms of antibody response…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00402831
- Testing
- ProQuad®
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles
mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-Bissau
The question that this project seeks to answer, is whether mobile phones can be used to increase the measles vaccination coverage and timeliness in Guinea-Bissau.
- Trial name
- mimi (NCT02662595)
- Testing
- SMS reminder message, Voice call + SMS message
- Where
- 3 sites in Guinea-Bissau
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV…
- Trial name
- NCT06389487
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 52 sites in United States, Australia and 4 more
- Volunteers
- 1,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a single intramuscular dose of the investigational respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine during subsequent…
- Trial name
- NCT05229068
- Testing
- RSV MAT
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
Safety and Efficacy of BARS13 in the Elderly
Advaccine Clinical Research are developing a vaccine called BARS13 for the active immunisation of infants (aged 6 months to 5 years old) and the elderly (aged 60-80 years old) for the seasonal prevention of Respiratory Syncytial…
- Trial name
- NCT04681833
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine (BARS13)
- Where
- 2 sites in Australia
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
Nipah Virus Infection
Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
The goal of this clinical trial is to test the safety and immunogenicity of PHV02 live, attenuated recombinant vesicular stomatitis virus vaccine expressing the Nipah Virus glycoprotein in healthy adult subjects.
- Trial name
- NCT06221813
- Testing
- PHV02, Lactated Ringer's
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC
Chickenpox, Rubella
MMR and Varicella Vaccine in Premature Infants
This research is designed to address the question, "Does the relative deficit in vaccine immunogenicity in extremely premature infants persist beyond the first 6 months of life?" We propose to measure the immunogenicity of…
- Conditions
- Chickenpox, Rubella, Rubeola, Mumps
- Trial name
- NCT00156559
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Rubella, Measles
Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella
Measles and rubella are highly contagious acute viral diseases. As per WHO, several evidences demonstrate the benefit for providing the universal access to vaccines containing measles and rubella antigens, mainly due to…
- Trial name
- BIOMR (NCT03148990)
- Testing
- Measles and Rubella vaccine, Measles, Mumps and Rubella vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Human Influenza, Respiratory Syncytial Virus Infections
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
This study evaluates a single use point of care diagnostic test in the diagnosis of influenza and other respiratory viral infections in adults. Participants will have a sample taken from their nose using a swab.
- Conditions
- Human Influenza, Respiratory Syncytial Virus Infections, Rhinoviral Infections, Enterovirus Infections
- Trial name
- SIMPLIFI (NCT04431050)
- Testing
- Point of care testing of respiratory viruses.
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Respiratory Syncytial Virus Infections
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.
Respiratory syncytial virus (RSV) is recognized worldwide as a significant pathogen causing lower respiratory tract infection in infants, the elderly, and immunocompromised patients, which may cause bronchiolitis or pneumonia…
- Trial name
- NCT07658534
- Testing
- Ziresovir (AK0529)
- Where
- 9 sites in China
- Volunteers
- 290 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
RSV Infection
Respiratory Syncytial Virus (RSV) Burden in Older Adults in Primary Care in The Netherlands
RSV infection is a leading cause of medical care in older adults, sometimes leading to hospital admission and severe outcomes. Although the majority of RSV infections are managed outside hospitals, little is known on the burden…
- Trial name
- RAPID (NCT06318936)
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- UMC Utrecht
Respiratory Syncytial Virus Infections
A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model
This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo control in the respiratory syncytial virus challenge model.
- Trial name
- NCT02094365
- Testing
- ALS-008176, vehicle
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Mumps
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.
- Trial name
- NCT05065177
- Testing
- Investigational live attenuated mumps vaccine, control live attenuated mumps vaccine
- Where
- China
- Volunteers
- 1,140 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Respiratory Syncytial Virus Infections
A Study of AK0529 in Infants Hospitalized With RSV
This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single dose of AK0529 in infants hospitalized with respiratory syncytial virus (RSV).
- Trial name
- NCT02460016
- Testing
- AK0529
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Viral Pneumonia
Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
The goal of this Phase 2 study is to assess the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection.
- Trial name
- INVENT (NCT06999603)
- Testing
- SNG001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Synairgen Research Ltd.
Measles
Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
This study will be an epidemiological inquiry, in communicating confirmed measles cases. The contacts of the index cases will be asked about the measles diagnosis and previous measles vaccination, and will have their vaccination…
- Trial name
- NCT05592756
- Where
- Brazil
- Volunteers
- 2,964 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Bronchiolitis, Respiratory Syncytial Virus Infections
Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
The purpose of this study is to evaluate how two different aerosol medications may improve airway function in infants with respiratory illness.
- Trial name
- NCT00435994
- Testing
- Inhaled primatene will be given as a breathing treatment, Nasal Washing
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Indiana University
Pharmacokinetics, Healthy Volunteers
Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers
This is a single center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose (MAD), 7-day treatment period study in healthy subjects.
- Trial name
- NCT02668367
- Testing
- BTA-C585 oral capsules
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biota Pharmaceuticals, Inc.